Updated review of appetite pharmacology for obesity: GLP-1 agonists (most promising), cannabinoid CB1 antagonists (withdrawn for psychiatric side effects), and combination peptide approaches — the 2010 drug development landscape.
Key findingUpdated review of appetite pharmacology for obesity: GLP-1 agonists (most promising), cannabinoid CB1 antagonists (withdrawn for psychiatric side effe
What the researchers found
Updated review of appetite pharmacology for obesity: GLP-1 agonists (most promising), cannabinoid CB1 antagonists (withdrawn for psychiatric side effects), and combination peptide approaches — the 2010 drug development landscape.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Pharmacological management of appetite expression in obesity.
Nature reviews. Endocrinology, 6(5), 255-69
Citation
Halford, Jason C G; Boyland, Emma J; Blundell, John E; Kirkham, Tim C; Harrold, Joanne A. (2010). Pharmacological management of appetite expression in obesity.. Nature reviews. Endocrinology, 6(5), 255-69. https://doi.org/10.1038/nrendo.2010.19